ReviewMolecular biology reports2011
Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis.
Review in Molecular biology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.Arthritis research & therapy · 2018Trial
- Integrative transcriptomics-metabolomics reveals sphingolipid metabolic reprogramming in traditional Chinese medicine syndrome differentiation of rheumatoid arthritis.Frontiers in immunology · 2026Article
- Unveiling the pharmacological mechanisms of Spirulina platensis in rheumatoid arthritis rats through the integration of serum metabolomics, pathways analysis, and experimental validation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Investigating the underlying mechanisms of the ethanol extract of saussureae involucratae herba in anti-rheumatoid arthritis effect based on sphingolipidomics.Frontiers in pharmacology · 2025Article
- S1P/S1PR signaling pathway advancements in autoimmune diseases.Biomolecules & biomedicine · 2023Review
- The calcitonin receptor protects against bone loss and excessive inflammation in collagen antibody-induced arthritis.iScience · 2022Article
- The change of plasma metabolic profile and gut microbiome dysbiosis in patients with rheumatoid arthritis.Frontiers in microbiology · 2022Article
- Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients.Journal of translational medicine · 2021Article
- HDL and persistent inflammation immunosuppression and catabolism syndrome.Current opinion in lipidology · 2021Review
- Metabolic Targets for Treatment of Autoimmune Diseases.Immunometabolism · 2020Article
- Decreased Expression of Sphingosine-1-Phosphate Receptor 1 in the Blood Leukocyte of Rheumatoid Arthritis Patients.Immune network · 2018Article
- Sphingolipidomic Profiling of Rat Serum by UPLC-Q-TOF-MS: Application to Rheumatoid Arthritis Study.Molecules (Basel, Switzerland) · 2018Article
- Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis.Arthritis research & therapy · 2017Review
- Metabolomics in rheumatic diseases: desperately seeking biomarkers.Nature reviews. Rheumatology · 2016Review
- Targeting of proangiogenic signalling pathways in chronic inflammation.Nature reviews. Rheumatology · 2016Review
- Protein unfolding allows use of commercial antibodies in an apolipoprotein M sandwich ELISA.Journal of lipid research · 2015Article
- Dynamic Cross Talk between S1P and CXCL12 Regulates Hematopoietic Stem Cells Migration, Development and Bone Remodeling.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.International journal of molecular sciences · 2013Article
- Tetrandrine Inhibits the Wnt/ β -Catenin Signalling Pathway and Alleviates Osteoarthritis: An In Vitro and In Vivo Study.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Sphingolipids: a potential molecular approach to treat allergic inflammation.Journal of allergy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which has as its primary target, the synovial tissues and articular cartilage. The current pharmacological treatment of RA includes non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying anti-rheumatic drugs. Newer biological agents that work by inactivation of proinflammatory cytokines are available for treatment of RA. Sphingosine-1-phosphate (S1P) is a bioactive lipid that is generated from phosphorylation of sphingosine by activation of sphingosine kinase, and has been implicated as an important mediator in pathophysiological processes, including cell growth, differentiation, migration and survival, and angiogenesis. Several studies have explored the role of S1P in the pathogenesis of RA. The aim of this article was to review the biology and distribution of S1P, together with its role in RA, and to discuss its potential as a therapeutic target for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.